TEPADINA® 400mg/ (thiotepa) is a ready-to-use bag indicated as conditioning treatment prior to haematopoietic progenitor cell transplantation in haematological diseases and solid tumours.
C-PTBE-01 has shown a strong steroid-sparing effect in two clinical safety and efficacy studies in patients with brain tumors and peritumoral brain edema (PTBE). C-PTBE-01 can lead to a market reduction or complete replacement of steroid use. This can alleviate the severe steroid-induced side effects and thus improve the quality of life of those affected.
Delivers siRNA, antisense oligonucleotides, linear or circular mRNA and other RNA modalities to extrahepatic tissues - demonstrated across various indications in oncology (e.g. PDAC, breast cancer, ovarian cancer, lung cancer, melanoma, ATLL, TME), and inflammatory / autoimmune diseases (e.g. OA, RA, enterocolitis), CV (e.g. atherosclerosis, aortic aneurysm)